Indefinite Delivery Contract SPE2DR25D1075

The Defense Logistics Agency (DLA) Troop Support Medical awarded a $999,999,999 single award Indefinite Delivery Contract (IDC) to Amerisourcebergen Drug Corp to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. This IDC, which runs through December 2036, serves as a primary vehicle for procuring specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. The contract encompasses critical medical commodities required to support normal day-to-day operations, as well as planned and unplanned contingency, Prime Vendor Readiness (PVR), and War Readiness Materiel (WRM) for Continental United States (CONUS) and Outside the Continental United States (OCONUS) locations. This IDC is part of DLA's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional contracts to increase the Department of Defense's resiliency and access to vital pharmaceuticals during times of contingency or natural disasters.

The PPV-G GEN V solicitation is an unrestricted, fully competitive acquisition with an estimated total value of $30.3 billion. DLA intends to make multiple primary supplier awards for separate North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet (CONUS/OCONUS) regions, as well as a single back-up supplier award covering all regions. Awards will be made on a lowest price technically acceptable (LPTA) basis, with the government reserving the right to utilize a reverse auction to determine the final distribution fees. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with a vendor conference scheduled prior to the closing date.